Abstract:Background. To study the dynamic change of hepatocyte growth factor after hepatectomy in patients with primary liver cancer, and to analyse the prognostic value of hepatocyte growth factor and c-met for these patients.Methods. Thirty-one consecutive patients undergoing partial hepatectomy for liver cancer were studied. Serum hepatocyte growth factor level was determined by using enzyme-linked immunosorbent assay kit before and after operation, respectively. C-met protein and MRNA expressions in cancerous and paracancerous tissues were examined by immunohistochemical and RT-PCR methods, respectively. The correlations between clinical-pathologic parameters and the expressions of hepatocyte growth factor in serum and c-met in cancerous tissues were analysed, respectively.Results. Liver cancer patients had a significantly higher level of serum hepatocyte growth factor than normal controls (1.0424 +/- 0.498 ng/ml versus 0.685 +/- 0.115 ng/ml, p = 0.008). Serum hepatocyte growth factor level was positively affected by tumour size, node cirrhosis, portal vein tumour thrombi, cholangiocarcinoma (including combined hepatocellular carcinoma), poorly differentiated hepatocellular carcinoma and tumour recurrence or metastases. After hepatectomy, serum hepatocyte growth factor level peaked on the third postoperative day, and then declined, but did not return to normal level on the postoperative day 10. From the preoperative day to postoperative day 10, the level of serum hepatocyte growth factor had a decrease of percent (85.33 +/- 10.2%) in the group with large tumours (> 5 cm), but an elevation of percent (121.9 +/- 10.3%) in the group with small tumours (:55 cm). From the preoperative day to postoperative day 3, the level of serum hepatocyte growth factor had a higher elevation in the group with major resection than in the group with local resection (p = 0.016). Moderately or strongly positive expression of c-met protein was observed in 27 cancerous regions (27/31), and only in 5 paracancerous regions. The intensive expression of c-met MRNA was 100% (31/31) detectable in the cancerous tissues, but only 22.6% (7/31) in the paracancerous tissues. C-met protein expression in cancerous tissues was correlated with portal vein tumour thrombi, cholangiocarcinoma and tumour recurrence or metastases, and the expression in paracancerous tissues was correlated with node cirrhosis. No significant correlation was observed between the hepatocyte growth factor in serum and c-met in cancerous tissues.Conclusion. The over-expressions of the hepatocyte growth factor and c-met indicates an adverse prognosis for patients with liver cancer. The sustained high level of serum hepatocyte growth factor after hepatectomy may be a factor related to early tumour recurrence and metastasis. Liver regeneration may be a main factor leading to high level of serum hepatocyte growth factor in early postoperative stage. (c) 2006 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Serum Bfgf is a Potential Predictor for Metastatic Recurrence after Curative Resection of Hepatocellular Carcinoma

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Serum and Tissue Vascular Endothelial Growth Factor Predicts Prognosis in Hepatocellular Carcinoma Patients after Partial Liver Resection.

Serum Vascular Endothelial Growth Factor is a Potential Biomarker of Metastatic Recurrence after Curative Resection of Hepatocellular Carcinoma.

Prognostic Significance of Preoperative Serum Alpha- Fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China.

Serum TGF-β1 is a potential predictor for metastasis and recurrence after radical resection of hepatocellular carcinoma

Serum hepatocyte growth factor in gastric cancer and its clinical significance

Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma

[Study on the Prognostic Value of Hepatocyte Growth Factor and C-Met for Patients with Hepatocellular Carcinoma].

The Prognostic Significance of Preoperative Serum Levels of Extracellular Matrix Protein 1 in Patients with Hepatocellular Carcinoma

The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection.

The Prognostic Values of Serum Markers in Hepatocellular Carcinoma after Invasive Therapies Based on Real‐world Data

Dynamic Changes of Serum Hepatocyte Growth Factor in Patients with Gastric Cancer Before and after Operation and Its Relationship with Liver Metastasis

Serum Insulin-Like Growth Factor-1 (IGF-1): a Novel Prognostic Factor for Early Recurrence of Hepatocellular Carcinoma (HCC).

Elevation of Serum GGT and LDH Levels, Together with Higher BCLC Staging Are Associated with Poor Overall Survival from Hepatocellular Carcinoma: a Retrospective Analysis.

Prognostic Significance of Elevated Preoperative Serum CA125 Levels after Curative Hepatectomy for Hepatocellular Carcinoma.

Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma

Screening of Serum Biomarkers Related to the Tumor Recurrence Following Liver Transplantation for Hepatocellular Carcinoma

Serum interleukin-18 as a prognostic factor for hepatocellular carcinoma patients

Prognostic Value of Serum Α‐fetoprotein Level As an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis

The Clinical Value of Hepatocyte Growth Factor and Its Receptor--c-met for Liver Cancer Patients with Hepatectomy.